Mga Batayang Estadistika
| LEI | 549300ULW08F62IJML11 |
| CIK | 1676725 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to IDEAYA Biosciences, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2025 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commissio |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38915 ID |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission |
|
| August 5, 2025 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) IDEAYA Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid 1 Equity 2023 |
|
| August 5, 2025 |
IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update • Phase 2/3 trial of the darovasertib and crizotinib combination in 1L HLA-A2-negative metastatic uveal melanoma (MUM) on track to report median PFS data by year-end 2025; potential to enable a U.S. accelerated approval filing • First-reported median overall survival data in over 40 1L |
|
| August 5, 2025 |
As filed with the Securities and Exchange Commission on August 5, 2025 As filed with the Securities and Exchange Commission on August 5, 2025 Registration No. |
|
| August 5, 2025 |
Non-Employee Director Compensation Program. Exhibit 10.1 IDEAYA Biosciences, Inc. Non-Employee Director Compensation Program Amended effective as of June 23, 2025 This IDEAYA Biosciences, Inc. (the “Company”) Non-Employee Director Compensation Program (this “Program”) has been adopted under the Company’s 2019 Incentive Award Plan (the “Plan”) and shall be effective upon the closing of the Company’s initial public offering of its common stoc |
|
| August 5, 2025 |
Amendment, effective as of May 21, 2025, to the 2023 Employment Inducement Award Plan. Exhibit 10.3 Amendment to the IDEAYA Biosciences, Inc. 2023 Employment Inducement Award Plan This amendment (the “Amendment”) to the IDEAYA Biosciences, Inc. 2023 Employment Inducement Award Plan (the “Plan”) is effective as of May 21, 2025, the date the board of directors (the “Board”) of IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”), approved the Amendment as set forth herein. |
|
| August 5, 2025 |
Employment Agreement by and between IDEAYA Biosciences, Inc. and Joshua Bleharski, Ph.D. Exhibit 10.2 IDEAYA BIOSCIENCES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into between IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”) and Joshua Bleharski (“Executive” and, together with the Company, the “Parties”) effective as of May 1, 2025 (the “Effective Date”). WHEREAS, the Company desires to assure itself of the services of Executive |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38915 I |
|
| May 6, 2025 |
Employment Agreement Addendum by and between IDEAYA Biosciences, Inc. and Douglas Snyder. Exhibit 10.3 IDEAYA BIOSCIENCES, INC. EMPLOYMENT AGREEMENT ADDENDUM The Employment Agreement between IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”) and Douglas Snyder (“Executive” and, together with the Company, the “Parties”) dated September 18, 2024 (the “Employment Agreement”) is hereby amended, effective March 28, 2025, as follows: Section 3 (b) of the Employment Agreement is |
|
| May 6, 2025 |
Exhibit 10.4 Execution Copy CLINICAL STUDY COLLABORATION AND SUPPLY AGREEMENT This CLINICAL STUDY COLLABORATION AND SUPPLY AGREEMENT (this “Agreement”), made as of February 12, 2025 (the “Effective Date”), is by and between Gilead Sciences, Inc., having a place of business at 333 Lakeside Drive, Foster City, CA 94404 (“Gilead”), and IDEAYA Biosciences, Inc., having a place of business at 5000 Shor |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 6, 2025 |
Employment Agreement by and between IDEAYA Biosciences, Inc. and Andres Ruiz Briseno. Exhibit 10.2 IDEAYA BIOSCIENCES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into between IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”) and Andres Ruiz Briseno (“Executive” and, together with the Company, the “Parties”) effective as of March 28, 2025 (the “Effective Date”). WHEREAS, the Company desires to assure itself of the services of Exec |
|
| May 6, 2025 |
IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update • ~$1.05 billion of cash, cash equivalents and marketable securities as of March 31, 2025, and an updated cash runway guidance into 2029; commercial readiness activities ongoing • Over 300 patients enrolled in darovasertib and crizotinib registrational 1L HLA-A2-negative MUM trial; targe |
|
| May 6, 2025 |
Non-Employee Director Compensation Program Exhibit 10.1 IDEAYA Biosciences, Inc. Non-Employee Director Compensation Program Amended effective as of January 1, 2025 This IDEAYA Biosciences, Inc. (the “Company”) Non-Employee Director Compensation Program (this “Program”) has been adopted under the Company’s 2019 Incentive Award Plan (the “Plan”) and shall be effective upon the closing of the Company’s initial public offering of its common st |
|
| May 6, 2025 |
Insider Trading Compliance Policy. Exhibit 19.1 IDEAYA BIOSCIENCES, INC. INSIDER TRADING compliance POLICY (Adopted: April 4, 2019) (Effective as of: May 28, 2019) (Amended as of: April 30, 2025) This Insider Trading Compliance Policy (this “Policy”) of IDEAYA Biosciences, Inc. (the “Company”) consists of seven sections: • Section I provides an overview; • Section II sets forth the Company’s policies prohibiting insider trading; • |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2025 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission |
|
| February 18, 2025 |
Exhibit 10.19(b) AMENDMENT NUMBER ONE TO OPTION AND LICENSE AGREEMENT This Amendment Number One to Option and License Agreement (“Amendment No. 1”) is entered into as of December 12, 2024 (the “Amendment No. 1 Effective Date”), by and between Biocytogen Pharmaceuticals (Beijing) Co., Ltd., organized under the laws of China, having an address at No.12, Baoshen South Street, Daxing Bio-Medicine Indu |
|
| February 18, 2025 |
As filed with the Securities and Exchange Commission on February 18, 2025 As filed with the Securities and Exchange Commission on February 18, 2025 Registration No. |
|
| February 18, 2025 |
Employment Agreement by and between IDEAYA Biosciences, Inc. and Stu Dorman. Exhibit 10.12 IDEAYA BIOSCIENCES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into between IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”) and Stu Dorman (“Executive” and, together with the Company, the “Parties”) effective as of December 1, 2024 (the “Effective Date”). WHEREAS, the Company desires to assure itself of the services of Executive |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38915 IDEAYA Bioscien |
|
| February 18, 2025 |
Insider Trading Compliance Policy Exhibit 19.1 IDEAYA BIOSCIENCES, INC. INSIDER TRADING compliance POLICY (Adopted: April 4, 2019) (Effective as of: May 28, 2019) (Amended as of: October 30, 2024) This Insider Trading Compliance Policy (this “Policy”) of IDEAYA Biosciences, Inc. (the “Company”) consists of seven sections: • Section I provides an overview; • Section II sets forth the Company’s policies prohibiting insider trading; |
|
| February 18, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) IDEAYA Biosciences, Inc. |
|
| February 18, 2025 |
Exhibit 10.27 LICENSE AGREEMENT This LICENSE AGREEMENT (the “Agreement”) is entered into as of December 27th, 2024 (the “Effective Date”), by and between Jiangsu Hengrui Pharmaceuticals Co., Ltd., organized under the laws of the People’s Republic of China, having an address at No. 7 Kunlunshan Road, Lianyungang, Jiangsu Province 222047, China and its Affiliates (“Hengrui”), and IDEAYA Biosciences, |
|
| February 18, 2025 |
Exhibit 10.20(f) Amendment No. 5 to Agreement (“Amendment No. 5”) Amendment No. 5 Date: Dec 16, 2024 Name of Original Agreement: Clinical Trial Collaboration and Supply Agreement (the “Original Agreement,” and together with any previous amendments which may be described below, the “Agreement”) Effective Date of Original Agreement: March 11, 2020 Parties: Pfizer Inc. (“Pfizer”) and Ideaya Bioscienc |
|
| February 18, 2025 |
Exhibit 10.25(b) Execution Version FIRST AMENDMENT TO LEASE 5000 Shoreline Court THIS FIRST AMENDMENT TO OFFICE LEASE (this “Amendment”) is made as of May 10, 2024 (the “Amendment Effective Date”), by and between DW LSP 5000 SHORELINE LLC, a Delaware limited liability company (“Landlord”), and IDEAYA BIOSCIENCES, INC., a Delaware corporation (“Tenant”). RECITALS A. Pursuant to that certain Lease d |
|
| February 18, 2025 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 IDEAYA Biosciences (“we,” “us,” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, $0.0001 par value per share (“common stock”). Description of Capital Stock The following summary describ |
|
| February 13, 2025 |
Exhibit 99.1 IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update • Over 230 patients enrolled in potential registration-enabling trial in 1L HLA-A2-negative MUM, and median PFS readout targeted by year-end 2025 • 95 patients enrolled in neoadjuvant UM trial and targeting clinical data and regulatory update(s) in H1 2025, including visio |
|
| February 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2025 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commiss |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2025 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commiss |
|
| December 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2024 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commiss |
|
| December 30, 2024 |
Exhibit 99.1 IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors • Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC) • DLL3 highly expressed in Small Cell Lung Cancer (SCLC) and Neuroendocrine Tumors (NETs), respec |
|
| November 14, 2024 |
SC 13G/A 1 sc13ga207422idya11142024.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 IDEAYA Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 pa |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-389 |
|
| November 4, 2024 |
IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update • Enrollment in darovasertib + crizotinib 1L HLA-A2+ MUM potential Ph2/3 registration-enabling trial is ahead of schedule and has exceeded 150 patients • Successful FDA Type C meeting and targeting initiation of Ph3 registration-enabling trial for darovasertib in neoadjuvant UM in H1 2025; Phase 2 ne |
|
| November 4, 2024 |
Employment Agreement by and between IDEAYA Biosciences, Inc. and Douglas Snyder. Exhibit 10.2 IDEAYA BIOSCIENCES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into between IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”) and Doug Snyder (“Executive” and, together with the Company, the “Parties”) effective as of September 18, 2024 (the “Effective Date”). WHEREAS, the Company desires to assure itself of the services of Executiv |
|
| November 4, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commissi |
|
| November 4, 2024 |
Exhibit 10.1 OPTION AND LICENSE Agreement This Option and License Agreement (the “Agreement”) is entered into as of July 30, 2024 (the “Effective Date”), by and between Biocytogen Pharmaceuticals (Beijing) Co., Ltd., organized under the laws of China, having an address at No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, China 102609 (“Biocytogen”), and IDEA |
|
| October 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2024 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commissi |
|
| October 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2024 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commissio |
|
| October 4, 2024 |
Exhibit 99.1 IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium South San Francisco, CA, October 4, 2024– IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announ |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2024 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commis |
|
| August 6, 2024 |
Amendment, effective as of June 25, 2024, to the 2023 Employment Inducement Award Plan. EX-99.1(c) Exhibit 99.1(c) Amendment to the IDEAYA Biosciences, Inc. 2023 Employment Inducement Award Plan This amendment (the “Amendment”) to the IDEAYA Biosciences, Inc. 2023 Employment Inducement Award Plan (the “Plan”) is effective as of June 25, 2024, the date the board of directors (the “Board”) of IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”), approved the Amendment as se |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38915 ID |
|
| August 6, 2024 |
IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update • Darovasertib achieves triple-digit enrollment in Phase 2/3 trial in 1L HLA-A2*02:01(-) MUM; and >50 patients enrolled in Phase 2 neoadjuvant UM study • ASCO 2024 oral presentation of darovasertib in neoadjuvant UM; FDA Type C meeting for neoadjuvant UM in Q3’24 and targeting Phase 2 neoadjuvant UM |
|
| August 6, 2024 |
As filed with the Securities and Exchange Commission on August 6, 2024 S-8 As filed with the Securities and Exchange Commission on August 6, 2024 Registration No. |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A Amendment No. 1 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Num |
|
| August 6, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) IDEAYA Biosciences, Inc. |
|
| July 31, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2024 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission |
|
| July 31, 2024 |
Exhibit 99.1 IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen • Option for an exclusive worldwide license for potential first-in class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC) program • B7H3/PTK7 co-expression found in multiple solid tumor types, including double-digit p |
|
| July 11, 2024 |
Exhibit 1.1 IDEAYA Biosciences, Inc. 7,228,572 Shares of Common Stock and Pre-Funded Warrants to Purchase 285,715 Shares of Common Stock Underwriting Agreement July 9, 2024 J.P. MORGAN SECURITIES LLC GOLDMAN SACHS & CO. LLC JEFFERIES LLC RBC CAPITAL MARKETS, LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, Ne |
|
| July 11, 2024 |
Form of July 2024 Pre-funded Warrant. Exhibit 4.1 IDEAYA BIOSCIENCES, INC. [FORM OF] WARRANT TO PURCHASE SHARES OF COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. CS—[ ] Original Issue Date: [•] [ ], 2024 IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered |
|
| July 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2024 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission F |
|
| July 10, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-272936 Prospectus supplement (To the Prospectus dated June 26, 2023) 7,228,572 Shares of Common Stock Pre-funded Warrants to Purchase 285,715 Shares of Common Stock IDEAYA Biosciences, Inc. is offering 7,228,572 shares of its common stock and, in lieu of offering shares of its common stock to certain investors, pre-funded warr |
|
| July 10, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) IDEAYA Biosciences, Inc. |
|
| July 9, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-272936 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. |
|
| July 9, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2024 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission F |
|
| July 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2024 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission F |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2024 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission F |
|
| May 31, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2024 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission F |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38915 I |
|
| May 7, 2024 |
Exhibit 10.1 Clinical Trial Collaboration and Supply Agreement by and between MSD International Business GmbH and Collaborator (as defined below) Clinical Trial Collaboration and Supply Agreement - Information Sheet MSD Agreement Number (LKR Number) [***] Collaborator Entity Name IDEAYA Biosciences, Inc. Collaborator Address 7000 Shoreline Court, Suite 350, South San Francisco, CA 94080 Collaborat |
|
| May 7, 2024 |
IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update Exhibit 99.1 IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update • ASCO 2024 oral presentation of darovasertib neoadjuvant UM Phase 2 investigator-sponsored trial on June 3rd, and targeting neoadjuvant UM update in over 30 patients from Phase 2 company-sponsored trial and regulatory guidance both in H2 2024 • Selected move-forward Phase 2 dose for IDE |
|
| May 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| March 12, 2024 |
Exhibit 99.1 IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer • Trial will evaluate IDE161, IDEAYA’s investigational PARG inhibitor, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with MSI-high and MSS endometrial cancer • Potential first-in-class PARG inhibitor, in co |
|
| March 12, 2024 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2024 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission |
|
| February 20, 2024 |
Policy for Recovery of Erroneously Awarded Compensation. Exhibit 97 IDEAYA BIOSCIENCES, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION IDEAYA Biosciences, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of November 13, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject to |
|
| February 20, 2024 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 IDEAYA Biosciences (“we,” “us,” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, $0.0001 par value per share (“common stock”). Description of Capital Stock The following summary describ |
|
| February 20, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2024 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commiss |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38915 IDEAYA Bioscien |
|
| February 20, 2024 |
Exhibit 99.1 IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update • Targeting two independent Phase 2 clinical efficacy updates for darovasertib in neoadjuvant uveal melanoma (UM) in mid-2024, including from the Phase 2 IST and Phase 2 company-sponsored study • Targeting FDA regulatory guidance on darovasertib in neoadjuvant UM indicatio |
|
| February 20, 2024 |
Exhibit 10.25 OFFICE LEASE AGREEMENT BETWEEN AAT TORREY 13-14, LLC AS LANDLORD AND IDEAYA BIOSCIENCES, INC. AS TENANT STANDARD FORM MODIFIED GROSS OFFICE LEASE This Standard Form Modified Gross Office Lease ("Lease") is entered into effective as of November 14, 2023, between AAT TORREY 13-14, LLC, a Delaware limited liability company ("Landlord"), and IDEAYA BIOSCIENCES, INC., a Delaware corporati |
|
| February 20, 2024 |
Exhibit 10.23 EXECUTION COPY CLINICAL STUDY COLLABORATION AND SUPPLY AGREEMENT This CLINICAL STUDY COLLABORATION AND SUPPLY AGREEMENT (this “Agreement”), made as of November 29, 2023 (the “Effective Date”), is by and between Gilead Sciences, Inc., having a place of business at 333 Lakeside Drive, Foster City, CA 94404 (“Gilead”), and IDEAYA Biosciences, Inc., having a place of business at 7000 Sho |
|
| February 20, 2024 |
Non-Employee Director Compensation Program. Exhibit 10.13 IDEAYA Biosciences, Inc. Non-Employee Director Compensation Program Amended effective as of January 1, 2024 This IDEAYA Biosciences, Inc. (the “Company”) Non-Employee Director Compensation Program (this “Program”) has been adopted under the Company’s 2019 Incentive Award Plan (the “Plan”) and shall be effective upon the closing of the Company’s initial public offering of its common s |
|
| February 20, 2024 |
As filed with the Securities and Exchange Commission on February 20, 2024 As filed with the Securities and Exchange Commission on February 20, 2024 Registration No. |
|
| February 20, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) IDEAYA Biosciences, Inc. |
|
| February 14, 2024 |
IDYA / IDEAYA Biosciences, Inc. / Avidity Partners Management LP Passive Investment SC 13G/A 1 d1098037113g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* IDEAYA Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 45166A102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| February 14, 2024 |
SC 13G/A 1 sc13ga107422idya02142024.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 IDEAYA Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 pa |
|
| February 13, 2024 |
IDYA / IDEAYA Biosciences, Inc. / Logos Global Management LP Passive Investment SC 13G/A 1 idya13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) IDEAYA Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 45166A102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| February 13, 2024 |
IDYA / IDEAYA Biosciences, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv01162-ideayabiosciencesinc.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Ideaya Biosciences Inc Title of Class of Securities: Common Stock CUSIP Number: 45166A102 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursu |
|
| February 7, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* IDEAYA Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45166A102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursua |
|
| February 1, 2024 |
IDYA / IDEAYA Biosciences, Inc. / CANAAN X L.P. - SC 13G/A Passive Investment SC 13G/A 1 d723295dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) IDEAYA Biosciences, Inc. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 45166A 102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) C |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2024 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commissi |
|
| January 19, 2024 |
Exhibit 10.1 Execution Version OPEN MARKET SALES AGREEMENTSM January 19, 2024 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of |
|
| January 19, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2024 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commissi |
|
| January 19, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) IDEAYA Biosciences, Inc. |
|
| January 19, 2024 |
Up to $350,000,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-272936 PROSPECTUS SUPPLEMENT (To prospectus dated June 26, 2023) Up to $350,000,000 Common Stock We have entered into a sales agreement with Jefferies LLC, or Jefferies, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreem |
|
| January 18, 2024 |
IDYA / IDEAYA Biosciences, Inc. / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2*) IDEAYA BIOSCIENCES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 45166A102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of t |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2024 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commissi |
|
| January 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commissio |
|
| December 4, 2023 |
Exhibit 99.1 IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy® and IDE397 Combination in MTAP-Deletion Bladder Cancer - Entered into Clinical Study Collaboration and Supply Agreement with Gilead to evaluate IDE397, IDEAYA’s MAT2A inhibitor, in combination with sacituzumab-govitecan-hziy (“Trodelvy”) Gilead’s Trop-2 directed ADC, in MTAP-deletion bladder cance |
|
| December 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2023 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commiss |
|
| November 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commiss |
|
| November 7, 2023 |
IDEAYA Biosciences, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update Exhibit 99.1 IDEAYA Biosciences, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update • Strong balance sheet of $511.1 million of cash, cash equivalents and marketable securities as of September 30, 2023, supplemented by $134.7 million estimated net proceeds from subsequent follow-on financing and $10.0 million receivable from GSK milestones • Multiple patients dosed and |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-389 |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commissi |
|
| October 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2023 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commissi |
|
| October 27, 2023 |
Form of October 2023 Pre-funded Warrant. Exhibit 4.1 IDEAYA BIOSCIENCES, INC. [FORM OF] WARRANT TO PURCHASE SHARES OF COMMON STOCK Warrant No. CS - [ ] Number of Shares: [ ] (subject to adjustment) Original Issue Date: [●] [ ], 2023 IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its re |
|
| October 27, 2023 |
Exhibit 1.1 IDEAYA Biosciences, Inc. 5,000,000 Shares of Common Stock and pre-funded warrants to purchase 319,150 Shares of Common Stock Underwriting Agreement October 24, 2023 J.P. MORGAN SECURITIES LLC GOLDMAN SACHS & CO. LLC JEFFERIES LLC RBC CAPITAL MARKETS, LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York |
|
| October 26, 2023 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) IDEAYA Biosciences, Inc. |
|
| October 26, 2023 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-272936 Prospectus supplement (To the Prospectus dated June 26, 2023) 5,000,000 Shares of Common Stock Pre-funded Warrants to Purchase 319,150 Shares of Common Stock IDEAYA Biosciences, Inc. is offering 5,000,000 of shares of its common stock and, in lieu of offering shares of its common stock to certain investors, pre-funded w |
|
| October 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2023 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commissi |
|
| October 24, 2023 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-272936 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. |
|
| October 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2023 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commissi |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2023 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commis |
|
| August 10, 2023 |
Exhibit 10.2 Amendment No. 1 to Agreement (“Amendment No. 1”) Amendment No. 1 Date: May 10, 2023 Name of Original Agreement: Clinical Trial Collaboration and Supply Agreement (the “Agreement”) Effective Date of Original Agreement: March 9, 2022 Parties: Pfizer Inc. (“Pfizer”) and Ideaya Biosciences, Inc. (“Ideaya”) WHEREAS, the Parties entered into the Agreement, for the Global Phase 2, registrati |
|
| August 10, 2023 |
Exhibit 10.3 Execution Version LEASE BY AND BETWEEN DW LSP 5000 SHORELINE, LLC, a Delaware limited liability company as Landlord and IDEAYA BIOSCIENCES, INC. a Delaware corporation as Tenant For Premises located at 5000 Shoreline Court South San Francisco, California ACTIVE\201239119.12 #201239119v12 - DW Life Sciences DIVCO IDEAYA Biosciences 500 Shoreline Court...docx ACTIVE\201239119.12 Exhibit |
|
| August 10, 2023 |
IDEAYA Biosciences, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update Exhibit 99.1 IDEAYA Biosciences, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update • Strong balance sheet of $510.1 million of cash, cash equivalents and marketable securities as of June 30, 2023 anticipated to fund operations into 2027 • Initiated Phase 2/3 registrational trial for darovasertib and crizotinib combination in first-line HLA-A2 negative metastatic UM, a |
|
| August 10, 2023 |
Exhibit 10.5 IDEAYA BIOSCIENCES, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”) is entered into between IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”) and Andres Ruiz Briseno (“Executive” and, together with the Company, the “Parties”) effective as of July 1, 2023 (the “Effective Date”). This Agreement supersedes in |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38915 ID |
|
| August 10, 2023 |
Exhibit 10.1 Amendment No. 4 to Agreement (“Amendment No. 4”) Amendment No. 4 Date: May 10, 2023 Name of Original Agreement: Clinical Trial Collaboration and Supply Agreement (the “Original Agreement,” and together with any previous amendments which may be described below, the “Agreement”) Effective Date of Original Agreement: March 11, 2020 Parties: Pfizer Inc. (“Pfizer”) and Ideaya Biosciences, |
|
| August 10, 2023 |
Non-Employee Director Compensation Program. Exhibit 10.4 IDEAYA Biosciences, Inc. Non-Employee Director Compensation Program Amended as of June 6, 2023 This IDEAYA Biosciences, Inc. (the “Company”) Non-Employee Director Compensation Program (this “Program”) has been adopted under the Company’s 2019 Incentive Award Plan (the “Plan”) and shall be effective upon the closing of the Company’s initial public offering of its common stock (the “IPO |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commissio |
|
| July 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2023 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission |
|
| June 30, 2023 |
Exhibit 1.1 Execution Version OPEN MARKET SALES AGREEMENTSM June 26, 2023 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission |
|
| June 26, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) IDEAYA Biosciences, Inc. |
|
| June 26, 2023 |
As filed with the Securities and Exchange Commission on June 26, 2023 S-3ASR Table of Contents As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. |
|
| June 26, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) IDEAYA Biosciences, Inc. |
|
| June 26, 2023 |
EX-4.2 Exhibit 4.2 IDEAYA BIOSCIENCES, INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. |
|
| June 26, 2023 |
Up to $250,000,000 Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-272936 PROSPECTUS SUPPLEMENT (To prospectus dated June 26, 2023) Up to $250,000,000 Common Stock We have entered into a sales agreement with Jefferies LLC, or Jefferies, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission F |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission F |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2023 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission F |
|
| May 16, 2023 |
Exhibit 99.1 IDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer to Support Registrational Trial Evaluating Darovasertib and Crizotinib Combination in First-Line Metastatic Uveal Melanoma Amended clinical trial collaboration and supply agreements with Pfizer to support evaluation of IDEAYA’s planned Phase 2/3 registrational clinical trial to evaluate Daro + Crizo in 1L |
|
| May 9, 2023 |
IDEAYA Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update Exhibit 99.1 IDEAYA Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update • Strong balance sheet of $351.2 million of cash, cash equivalents and marketable securities as of March 31, 2023 supplemented by $188.7 million estimated net proceeds from closing of underwritten public offering on April 27, 2023, anticipated to fund operations into 2027 • Initiating Ph |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38915 I |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2023 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission |
|
| April 27, 2023 |
Exhibit 1.1 IDEAYA Biosciences, Inc. 7,439,201 Shares of Common Stock and pre-funded warrants to purchase 2,020,270 Shares of Common Stock Underwriting Agreement April 24, 2023 J.P. MORGAN SECURITIES LLC JEFFERIES LLC CITIGROUP GLOBAL MARKETS INC. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/ |
|
| April 27, 2023 |
Form of April 2023 Pre-funded Warrant. EX-4.1 Exhibit 4.1 IDEAYA BIOSCIENCES, INC. [FORM OF] WARRANT TO PURCHASE SHARES OF COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. CS—[ ] Original Issue Date: April [ ], 2023 IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its re |
|
| April 26, 2023 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-254606 Prospectus supplement (To the Prospectus dated April 20, 2021) 7,439,201 shares Pre-funded warrants to purchase 2,020,270 shares Common stock IDEAYA Biosciences, Inc. is offering 7,439,201 shares of its common stock and, in lieu of offering shares of its common stock to certain investors, pre-funded warrants to pu |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2023 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2023 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission |
|
| April 24, 2023 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-254606 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state where the offer or sale is not permi |
|
| April 14, 2023 |
DEF 14A 1 idya-def14a-2023.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| March 24, 2023 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated March 24, 2023 with respect to the Common Stock, $0.0001 par value per share of IDEAYA Biosciences, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance wit |
|
| March 24, 2023 |
IDYA / Ideaya Biosciences Inc / BIOTECHNOLOGY VALUE FUND L P - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 IDEAYA Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 45166A102 (CUSIP Number) March 14, |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission |
|
| March 7, 2023 |
EX-99.3(b) Exhibit 99.3(b) IDEAYA BIOSCIENCES, INC. 2023 EMPLOYMENT INDUCEMENT AWARD PLAN STOCK OPTION GRANT NOTICE IDEAYA Biosciences, Inc., a Delaware corporation, (the “Company”), pursuant to its 2023 Employment Inducement Award Plan, as may be amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”), an option to purchase the number of shares of the Comp |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2023 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission |
|
| March 7, 2023 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 IDEAYA Biosciences (“we,” “us,” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, $0.0001 par value per share (“common stock”). Description of Capital Stock The following summary describ |
|
| March 7, 2023 |
Non-Employee Director Compensation Program. Exhibit 10.11 IDEAYA Biosciences, Inc. Non-Employee Director Compensation Program Amended as of June 9, 2022 This IDEAYA Biosciences, Inc. (the “Company”) Non-Employee Director Compensation Program (this “Program”) has been adopted under the Company’s 2019 Incentive Award Plan (the “Plan”) and shall be effective upon the closing of the Company’s initial public offering of its common stock (the “IP |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38915 IDEAYA Bioscien |
|
| March 7, 2023 |
IDEAYA Biosciences, Inc. Reports 2022 Financial Results and Provides Business Update Exhibit 99.1 IDEAYA Biosciences, Inc. Reports 2022 Financial Results and Provides Business Update • Strong balance sheet of ~$373.1 million cash, cash equivalents and marketable securities as of December 31, 2022 is anticipated to fund planned operations into 2026 • Planning regulatory update on potential registration-enabling clinical trial for darovasertib / crizotinib combination in MUM followi |
|
| March 7, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) IDEAYA Biosciences, Inc. |
|
| March 7, 2023 |
Employment Agreement by and between IDEAYA Biosciences, Inc. and Darrin Beaupre. Exhibit 10.10 IDEAYA BIOSCIENCES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into between IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”) and Darrin Beaupre, M.D., PhD (“Executive” and, together with the Company, the “Parties”) effective as of November 21, 2022 (the “Effective Date”). WHEREAS, the Company desires to assure itself of the servic |
|
| March 7, 2023 |
2023 Employment Inducement Award Plan. EX-99.3(a) Exhibit 99.3(a) IDEAYA BIOSCIENCES, INC. 2023 EMPLOYMENT INDUCEMENT AWARD PLAN PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate employees who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities. DEFINITIONS As used in the Plan, the following words and phrases have the |
|
| March 7, 2023 |
As filed with the Securities and Exchange Commission on March 7, 2023 S-8 As filed with the Securities and Exchange Commission on March 7, 2023 Registration No. |
|
| February 27, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* IDEAYA Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45166A102 (CUSIP Number) February 15, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuan |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 IDEAYA Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 45166A102 (CUSIP Number) December |
|
| February 14, 2023 |
SC 13G/A 1 pt7213ga.htm SCHEDULE 13G/A, AMENDMENT #1 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) IDEAYA Biosciences, Inc. (Title |
|
| February 14, 2023 |
IDYA / Ideaya Biosciences Inc / Boxer Capital, LLC Passive Investment SC 13G/A 1 ff000174211713ga-ideaya.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* IDEAYA, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 45166A102 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate b |
|
| February 14, 2023 |
IDYA / Ideaya Biosciences Inc / Logos Global Management LP Passive Investment SC 13G/A 1 ideaya13ga1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) IDEAYA Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 45166A102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| February 14, 2023 |
IDYA / Ideaya Biosciences Inc / RTW INVESTMENTS, LP - IDEAYA BIOSCIENCES, INC. Passive Investment SC 13G/A 1 p23-0695sc13ga.htm IDEAYA BIOSCIENCES, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* IDEAYA Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45166A102 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statemen |
|
| February 14, 2023 |
IDYA / Ideaya Biosciences Inc / Avidity Partners Management LP Passive Investment SC 13G/A 1 d917619313g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* IDEAYA Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 45166A102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the app |
|
| February 9, 2023 |
SC 13G/A 1 p23-0717sc13ga.htm IDEAYA BIOSCIENCES, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* IDEAYA Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45166A102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statemen |
|
| February 1, 2023 |
IDYA / Ideaya Biosciences Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1*) IDEAYA BIOSCIENCES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 45166A102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of t |
|
| November 8, 2022 |
IDEAYA Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update Exhibit 99.1 IDEAYA Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update • Strong balance sheet of $393.9 million cash, cash equivalents and marketable securities as of September 30, 2022 is anticipated to fund planned operations into 2026 • Reported Phase 2 interim clinical data for darovasertib and crizotinib combination in MUM; subject to FDA guidance, tar |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-389 |
|
| November 8, 2022 |
Exhibit 10.1 CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT This CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (this “Agreement”), made as of July 26, 2022 (the “Effective Date”), is by and between Amgen Inc., a Delaware corporation, having its principal place of business at One Amgen Center Drive, Thousand Oaks, CA 91362 (“Amgen”), and IDEAYA Biosciences, Inc., having its principal place o |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commissi |
|
| October 27, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* IDEAYA Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45166A102 (CUSIP Number) October 17, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant |
|
| September 19, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2022 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commis |
|
| September 19, 2022 |
EX-1.1 2 d382258dex11.htm EX-1.1 Exhibit 1.1 Execution Version IDEAYA Biosciences, Inc. 7,619,048 Shares of Common Stock Underwriting Agreement September 14, 2022 J.P. MORGAN SECURITIES LLC JEFFERIES LLC CITIGROUP GLOBAL MARKETS INC. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Jefferies LL |
|
| September 15, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-254606 Prospectus supplement (To the Prospectus dated April 20, 2021) 7,619,048 shares Common stock IDEAYA Biosciences, Inc. is offering 7,619,048 shares of its common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol ?IDYA.? The last reported sale price of our common stock on the Nasdaq Glo |
|
| September 14, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-254606 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. |
|
| September 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2022 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commis |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38915 ID |
|
| August 15, 2022 |
IDEAYA Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update Exhibit 99.1 IDEAYA Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update ? Strong balance sheet of ~$324 million cash, cash equivalents and marketable securities as of June 30, 2022 is anticipated to fund planned operations into 2025 ? Initiated IDE397 Phase 2 monotherapy expansion cohorts and Phase 1 combination dose escalation cohorts in solid tumors with |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commissio |
|
| July 27, 2022 |
Exhibit 99.1 IDEAYA Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors ? Entered into Clinical Trial Collaboration and Supply Agreement with Amgen to clinically evaluate IDE397, IDEAYA?s investigational MAT2A inhibitor, in combination with AMG 193, Amgen?s investigational MTA-Cooperative PRMT5 inhibitor, in MTAP-null sol |
|
| July 27, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2022 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission |
|
| June 10, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 09, 2022 IDEAYA Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38915 47-4268251 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 10, 2022 |
Exhibit 10.3 Amendment No. 2 to Collaboration, Option and License Agreement This Amendment No. 2 (the ?Amendment No. 2?) to the Collaboration, Option and License Agreement entered into as of June 15, 2020 between GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LIMITED (?GSK?), a company registered in England and Wales (registered number 11721880), and IDEAYA Biosciences, Inc., (?IDEAYA?) a Delaware |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38915 I |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission F |
|
| May 10, 2022 |
EXECUTION Exhibit 10.1 CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT This CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (this ?Agreement?), made as of March 9, 2022 (the ?Effective Date?), is by and between IDEAYA Biosciences, Inc., having a place of business at 7000 Shoreline Ct, Suite 350, South San Francisco CA 94080 (?Ideaya?), and Pfizer Inc., having a place of business at 235 East 42 |
|
| May 10, 2022 |
IDEAYA Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update Exhibit 99.1 IDEAYA Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update ? Strong balance sheet of ~$346 million cash, cash equivalents and marketable securities as of March 31, 2022 is anticipated to fund planned operations into 2025 ? Targeting initiation of IDE397 Phase 1/2 monotherapy expansion and Phase 1 combination cohorts, and delivery of GSK option d |
|
| May 10, 2022 |
EXECUTION Exhibit 10.2 CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT This CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (this ?Agreement?), made as of March 9, 2022 (the ?Effective Date?), is by and between IDEAYA Biosciences, Inc., having a place of business at 7000 Shoreline Ct, Suite 350, South San Francisco CA 94080 (?Ideaya?), and Pfizer Inc., having a place of business at 235 East 42 |
|
| May 2, 2022 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated May 2, 2022 with respect to the Common Stock, $0.0001 par value per share of IDEAYA Biosciences, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with t |
|
| May 2, 2022 |
IDYA / Ideaya Biosciences Inc / BIOTECHNOLOGY VALUE FUND L P - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b) (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 6, 2022 |
IDEAYA Biosciences Appoints Catherine Mackey, Ph.D., to its Board of Directors Exhibit 99.1 IDEAYA Biosciences Appoints Catherine Mackey, Ph.D., to its Board of Directors - Dr. Mackey formerly served as Senior Vice President of Pfizer Worldwide Research and Development and as Director of Pfizer?s La Jolla Laboratories South San Francisco, CA, April 6, 2022 ? IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed t |
|
| April 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 05, 2022 IDEAYA Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38915 47-4268251 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 18, 2022 |
HARP / Harpoon Therapeutics Inc / Logos Global Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) IDEAYA Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 41358P106 (CUSIP Number) March 8, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| March 18, 2022 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 IDEAYA Biosciences (?we,? ?us,? or ?our?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, $0.0001 par value per share (?common stock?). Description of Capital Stock The following summary describ |
|
| March 18, 2022 |
Exhibit 10.18 Amendment No. 1 to Collaboration and License Agreement This Amendment No. 1 (the ?Amendment?) to the Collaboration, Option and License Agreement dated June 15, 2020 between GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LIMITED (?GSK?), a company registered in England and Wales (registered number 11721880), and IDEAYA Biosciences, Inc., (?IDEAYA?) a Delaware corporation having an offi |
|
| March 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38915 IDEAYA Bioscien |
|
| March 17, 2022 |
As filed with the Securities and Exchange Commission on March 17, 2022 As filed with the Securities and Exchange Commission on March 17, 2022 Registration No. |
|
| March 17, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) IDEAYA Biosciences, Inc. |
|
| March 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission |
|
| March 15, 2022 |
IDEAYA Biosciences, Inc. Reports 2021 Financial Results and Provides Business Update Exhibit 99.1 IDEAYA Biosciences, Inc. Reports 2021 Financial Results and Provides Business Update - Strong balance sheet of ~$368 million cash, cash equivalents and marketable securities as of December 31, 2021 is anticipated to fund planned operations into 2025 - Enrolling into IDE397 Cohort 6 with no observed drug-related serious adverse events and without observing maximum tolerated dose throug |
|
| February 18, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| February 18, 2022 |
IDYA / Ideaya Biosciences Inc / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.)* (Name of Issuer) IDEAYA Biosciences, Inc. (Title of Class of Securities) Common Stock, $0.0001 Par Value |
|
| February 14, 2022 |
IDYA / Ideaya Biosciences Inc / RTW INVESTMENTS, LP - IDEAYA BIOSCIENCES, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* IDEAYA Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45166A102 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule purs |
|
| February 14, 2022 |
SC 13G/A 1 sc13ga507422idya02142022.htm AMENDMENT NO. 5 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 5)1 IDEAYA Biosciences, Inc. (Name of Issuer) Common Stock, $0.000 |
|
| February 14, 2022 |
IDYA / Ideaya Biosciences Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ?.11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. *) IDEAYA BIOSCIENCES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 45166A102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of th |
|
| February 14, 2022 |
IDYA / Ideaya Biosciences Inc / Avidity Partners Management LP Passive Investment SC 13G/A 1 d917619313g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* IDEAYA Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 45166A102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the app |
|
| December 1, 2021 |
IDYA / Ideaya Biosciences Inc / Avidity Partners Management LP Passive Investment SC 13G 1 d9072682.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* IDEAYA Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 45166A102 (CUSIP Number) November 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| November 15, 2021 |
IDEAYA Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update Exhibit 99.1 IDEAYA Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update - Strong balance sheet of ~$386 million cash, cash equivalents and marketable securities is anticipated to fund planned operations into 2025 - Observed IDE397 preliminary clinical activity in early Phase 1 dose escalation cohorts, including pharmacodynamic modulation and tumor shrinkage |
|
| November 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commiss |
|
| November 15, 2021 |
Amended and Restated Employment Agreement by and between IDEAYA Biosciences, Inc. and Michael White. Exhibit 10.2 Certain information in this document (indicated by ####) has been omitted pursuant to Regulation S-K Item 601(a)(6). IDEAYA BIOSCIENCES, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the ?Agreement?) is entered into between IDEAYA Biosciences, Inc., a Delaware corporation (the ?Company?) and Michael White (?Executive? and, together with |
|
| November 15, 2021 |
Exhibit 10.1 Amendment No. 3 to Agreement (?Amendment No. 3?) Amendment No. 3 Date: August 9, 2021 Name of Original Agreement: Clinical Trial Collaboration and Supply Agreement (the ?Original Agreement,? and together with any previous amendments which may be described below, the ?Agreement?) Effective Date of Original Agreement: March 11, 2020 Parties: Pfizer Inc. (?Pfizer?) and Ideaya Biosciences |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-389 |
|
| August 11, 2021 |
IDYA / Ideaya Biosciences Inc / 5AM Ventures IV, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* IDEAYA Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45166A 102 (CUSIP Number) Rebecca Luci |
|
| August 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commissio |
|
| August 10, 2021 |
IDEAYA Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update Exhibit 99.1 IDEAYA Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update - Strong balance sheet of ~$400 million cash, cash equivalents and marketable securities is anticipated to fund planned operations into 2025 - Enrolling MTAP-deletion solid tumors patients into the IDE397 Phase 1 dose escalation and tumor biopsy cohorts; targeting to obtain additional c |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38915 ID |
|
| July 12, 2021 |
Exhibit 1.1 EXECUTION VERSION IDEAYA Biosciences, Inc. 4,637,681 Shares of Common Stock Underwriting Agreement July 7, 2021 J.P. MORGAN SECURITIES LLC CITIGROUP GLOBAL MARKETS INC. JEFFERIES LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Citigroup Global Markets Inc. 388 Greenwich Street |
|
| July 12, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2021 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission F |
|
| July 8, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-254606 Prospectus supplement (To the Prospectus dated April 20, 2021) 4,637,681 Shares Common stock IDEAYA Biosciences, Inc. is offering 4,637,681 shares of its common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol ?IDYA.? The last reported sale price of our common stock on the Nasdaq Glo |
|
| July 6, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-254606 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. |
|
| June 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2021 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission |
|
| June 14, 2021 |
Submission of Matters to a Vote of Security Holders 8-K 1 idya-8k20210614.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2021 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction |
|
| May 10, 2021 |
IDEAYA Biosciences, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update Exhibit 99.1 IDEAYA Biosciences, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update - Completed enrollment of initial dose escalation cohort of the Phase 1 clinical trial evaluating IDE397, a potential best-in-class MAT2A inhibitor for MTAP-deletion patients - Demonstrated IDE397 single-agent preclinical activity in a 40-plus MTAP-deletion PDX study across major solid t |
|
| May 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 idya-8k20210510.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2021 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction o |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38915 I |
|
| May 10, 2021 |
Exhibit 10.1 Amendment No. 2 to Agreement (?Amendment No. 2?) Amendment No. 2 Date: April 8, 2021 Name of Original Agreement: Clinical Trial Collaboration and Supply Agreement (the ?Original Agreement,? and together with any previous amendments which may be described below, the ?Agreement?) Effective Date of Original Agreement: March 11, 2020 Parties: Pfizer Inc. (?Pfizer?) and Ideaya Biosciences, |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 4)1 IDEAYA Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 45166A102 (CUSIP Number) April 27 |
|
| April 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 16, 2021 |
IDEAYA Biosciences, Inc. 7000 Shoreline Court, Suite 350 South San Francisco, California 94080 IDEAYA Biosciences, Inc. 7000 Shoreline Court, Suite 350 South San Francisco, California 94080 April 16, 2021 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Ada Sarmento, Staff Attorney Re: IDEAYA Biosciences, Inc. Registration Statement on Form S-3 (Registration No. 333-254606) Ladies |
|
| April 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* IDEAYA Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 45166A 102 (CUSIP Number) November 20, 2019 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule p |
|
| April 5, 2021 |
Exhibit 99.1 Joint Filing Agreement The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed jointly on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. The undersigned also agree that |
|
| March 23, 2021 |
Amended and Restated Employment Agreement by and between IDEAYA Biosciences, Inc. and Jason Throne. Exhibit 10.9 IDEAYA BIOSCIENCES, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is entered into between IDEAYA Biosciences, Inc., a Delaware corporation (the ?Company?) and Jason S. Throne (?Executive? and, together with the Company, the ?Parties?) effective as of February 24, 2021 (the ?Effective Date?). This Agreement supersedes in its entirety that ce |
|
| March 23, 2021 |
IDEAYA Biosciences, Inc. Reports Fourth Quarter 2020 Financial Results and Provides Business Update Exhibit 99.1 IDEAYA Biosciences, Inc. Reports Fourth Quarter 2020 Financial Results and Provides Business Update - Initiated Phase 1 clinical trial for IDE397, a potential best-in-class MAT2A inhibitor for patients having tumors with MTAP-deletion - Planning to present data at AACR in April 2021 for IDE397 (monotherapy efficacy in over forty PDX models with homozygous MTAP deletions across tumor t |
|
| March 23, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on March 23, 2021 Registration No. |
|
| March 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38915 IDEAYA Bioscien |
|
| March 23, 2021 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of March 23, 2021, IDEAYA had one class of common stock registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). The following summary describes our common stock and the material provisions of our amended and restated certifi |
|
| March 23, 2021 |
As filed with the Securities and Exchange Commission on March 23, 2021 Registration No. |
|
| March 23, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 idya-8k20210323.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2021 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction |
|
| March 23, 2021 |
Exhibit 4.4 IDEAYA BIOSCIENCES, INC. INDENTURE Dated as of , 20 [ ], as Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 4 Section 1.3. Incorporation by Reference of Trust Indenture Act. 5 Section 1.4. Rules of Construction. 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series. 5 Section 2.2 |
|
| February 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2021 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commiss |
|
| February 17, 2021 |
Exhibit 99.1 IDEAYA Biosciences Appoints Susan L. Kelley, M.D., an Industry Veteran in Medical Oncology and Clinical Development, to its Board of Directors - Dr. Susan L. Kelley was a former clinical development executive in oncology with Bayer and Bristol Myers Squibb, and led the development and regulatory approval of Nexavar? South San Francisco, CA, February 17, 2021 ? IDEAYA Biosciences, Inc. |
|
| February 16, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) IDEAYA Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 45166A 102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 16, 2021 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 16, 2021 PERCEPTIVE ADVISORS LLC |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* IDEAYA Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 45166A 102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 16, 2021 |
CUSIP No. 45166A 102 13G Exhibit 99.1 JOINT FILING STATEMENT We, the undersigned, hereby express our agreement that the attached statement on Schedule 13G relating to the Common Stock of IDEAYA Biosciences, Inc. is filed on behalf of each of us. Dated: February 16, 2021 Nextech V Oncology S.C.S., SICAV-SIF By: Nextech V GP S.à r.l. Its: General Partner By: /s/ Dalia Bleyer Dalia Bleyer, Managing M |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 IDEAYA Bioscience, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 45166A102 (CUSIP Number) December |
|
| January 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 22, 2021 |
Joint Filing Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock of IDEAYA Biosciences, Inc. |
|
| January 21, 2021 |
Open Market Sale AgreementSM by and between the Company and Jefferies LLC. EX-1.1 Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM January 20, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’ |
|
| January 21, 2021 |
Up to $90,000,000 Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-238849 PROSPECTUS SUPPLEMENT (To prospectus dated June 10, 2020) Up to $90,000,000 Common Stock We have entered into a sales agreement with Jefferies LLC, or Jefferies, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales a |
